نتایج جستجو برای: 1033
تعداد نتایج: 841 فیلتر نتایج به سال:
Recent clinical data indicates that the emergence of mutant drug-resistant kinase alleles may be particularly relevant for targeted kinase inhibitors. In order to explore how different classes of targeted therapies impact upon resistance mutations, we performed EGFR (epidermal-growth-factor receptor) resistance mutation screens with erlotinib, lapatinib and CI-1033. Distinct mutation spectra we...
Phase 1 clinical and pharmacokinetics evaluation of oral CI-1033 in patients with refractory cancer.
PURPOSE To determine the tolerability and pharmacokinetics of oral CI-1033, a pan-erbB tyrosine kinase inhibitor, administered over 14 consecutive days of a 21-day cycle. DESIGN Phase 1, multicenter trial involving patients with solid tumors that are refractory to standard therapy. CI-1033 was administered initially at 300 mg/day to a minimum cohort of three patients. Dose escalation proceede...
a Department of Chemistry and Biomolecular Science, and NanoBio Laboratory (NABLAB), Clarkson University, Potsdam NY 13699-5810, USA b Instituto de Catalisis y Petroleoquimica, CSIC. C/ Marie Curie, 2. 28049 Madrid, Spain c Procter and Gamble Company, Mason Business Center, 8700 Mason Montgomery Road Mason, Ohio 45040, USA d Research and Development Department, Procter and Gamble Company, Cinci...
آغاز چالشهای تازه در جهان طی دهه اول قرن بیست ویکم، عرصه سیاست بینالملل را پیچیدهتر از قبل ساخته است. در چنین شرایطی، تغییر در سیاست خارجی کشورها دور از انتظار نیست. از نتایج این وقایع در سطح نظام بینالملل در سالهای 1003 تا 1033 ؛ تغییر در سیاست خارجی کشور ژاپن بوده است. این تغییر با مولفهها، مفاهیم و انگارههای جدید؛ دیده می شود. در این پژوهش بدین پرسش پرداخته شده است که تحولات در ساختار، معنا ...
PURPOSE In phase I studies with oral CI-1033, dose-limiting toxicities were primarily gastrointestinal, supporting the exploration of i.v. dosing to achieve optimal drug exposures by increasing bioavailability. EXPERIMENTAL DESIGN Fifty-three patients with advanced nonhematologic malignancies received i.v. CI-1033 via 30-minute infusions (10-500 mg) on a thrice-weekly schedule. Pharmacokineti...
PURPOSE To determine the tolerability and pharmacokinetics of CI-1033 given daily for 7 days of a 21-day cycle. Tumor response and changes in erbB receptor tyrosine kinase activity in tumor and skin tissue were examined, and modulation of potential biomarkers in plasma was explored. DESIGN This was a dose-finding phase I study in patients with advanced solid malignancies. Patients were evalua...
Children born from mothers positive for autoantibodies against SSA/Ro and/or anti-SSB/La ribonucleoproteins may develop heart conduction tissue damage resulting in atrioventricular block and/or transient skin rash, liver enzyme abnormalities and anaemia/thrombocytopenia. Additional transient electrocardiographic abnormalities (sinus bradycardia, QT interval prolongation) have been reported. Suc...
Unraveling a Riddle Inside an Enigma? Bone Morphogenetic Protein Receptor-2 and Pulmonary Arterial Hypertension: Print ISSN: 0009-7330. Online ISSN: 1524-4571 Copyright © 2005 American Heart Association, Inc. All rights reserved. is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231 Circulation Research doi: 10.1161/01.RES.0000168922.54339.47 2005;96:1033-1035...
PURPOSE To determine the maximum tolerated dose of administrating CI-1033, an oral 4-anilinoquinazoline that irreversibly inhibits the tyrosine kinase domain of all erbB subfamilies, on an intermittent schedule, and assess the interaction of CI-1033 with food on the pharmacokinetic behavior. EXPERIMENTAL DESIGN Escalating doses of CI-1033 from a dose level of 300 mg/day for 7 days every other...
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید